Trial Profile

A Phase II Study for the Treatment of Psychosis in Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Oct 2023 Status changed from recruiting to completed.
07 Jan 2019 New trial record
18 Dec 2018 According to an IRLAB media release, based on advice in a recent FDA pre-IND meeting, the company received confirmation that performed and planned pre-clinical studies and CMC-program in the development of IRL790 are sufficient to apply for an IND.The authority, also provided clear guidance on the design of this phase II study for the treatment of psychosis in Parkinsons disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com